Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30845983 | 1.00 | CYP2A6 (0.60) | CYP2A6POLBCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL30274592 | 1.00 | CYP2A6 (0.60) | CYP2A6POLBCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL24316390 | 0.77 | CYP2A6 (0.48) | CYP2A6POLBCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL24048456 | 0.77 | CYP2A6 (0.46) | CYP2A6POLBCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL24047877 | 0.76 | CYP2A6 (0.44) | CYP2A6POLBCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL5673224 | 0.75 | CYP2A6 (0.65) | CYP2A6CYP1A2ALDH1A1HSD17B10TSHR | |
| SCHEMBL449348 | 0.75 | CYP2A6 (1.00) | CYP2A6CYP1A2ALDH1A1HSD17B10TSHR | |
| SCHEMBL1187756 | 0.75 | POLB (0.60) | CYP2A6POLBCYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL24047527 | 0.73 | CYP1A1 (0.43) | CYP2A6CYP1A2ALDH1A1HSD17B10TSHR | |
| Ammonia Solution, Strong SCHEMBL11476794 | 0.73 | CYP2A6 (0.95) | CYP2A6CYP1A2ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-3305792-B1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME | LG CHEMICAL LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-3305792-B1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME | LG CHEMICAL LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| CN-116438946-A | Organic light emitting device | 株式会社LG化学 | 2023-07-14 | — | — | CN | disclosed |
| CN-116419921-A | Compound and organic light emitting device comprising the same | 株式会社LG化学 | 2023-07-11 | — | — | CN | disclosed |
| EP-3305792-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME | LG Chem, Ltd. (KR) | 2018-04-11 | — | — | EP | disclosed |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG CHEM, LTD. (KR) | 2017-07-27 | — | — | US | disclosed |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG CHEM, LTD. (KR) | 2017-07-27 | — | — | US | disclosed |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG CHEM, LTD. (KR) | 2017-07-27 | — | — | US | disclosed |
| CN-106661037-A | Nitrogen-containing fused ring compound and organic light-emitting device using same | 株式会社LG化学 | 2017-05-10 | — | — | CN | disclosed |
| CN-103553866-B | A kind of method preparing adjacent two/trihalogenated benzene | ZHEJIANG NORMAL UNIVERSITY (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-103553866-A | Method for preparing o-dihalogeno/trihalogeno benzene | UNIV ZHEJIANG NORMAL | 2014-02-05 | — | — | CN | disclosed |
| US-5114896-A | Reaction product of magnesium, halogenated hydrocarbon, alkoxy compound, titanium compound, halogen-containing alcohol and solid halogenated hydrocarbon | TONEN CORPORATION (JP) | 1992-05-19 | — | — | US | disclosed |
| EP-0440813-A1 | METHOD OF PRODUCING CATALYST COMPONENT FOR OLEFIN POLYMERIZATION | Tonen Corporation (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-3989746-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | IKEDA MOHANDO CO., LTD. (JA) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CYP2A6 3249/4885POLB 1346/4885CYP1A2 4527/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP2A6 3178/4885POLB 2333/4885CYP1A2 4159/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP2A6 3961/4885POLB 1356/4885CYP1A2 4709/4885 |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, NOS1, NOLC1 | CYP2A6 1800/4885POLB 1068/4885CYP1A2 667/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CYP2A6 3105/4885POLB 1319/4885CYP1A2 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.